Regeneron Pharmaceuticals (LTS:0R2M) Inventories, Finished Goods : $110 Mil (As of Mar. 2025)

View and export this data going back to 2014. Start your Free Trial

What is Regeneron Pharmaceuticals Inventories, Finished Goods?

Regeneron Pharmaceuticals's quarterly finished goods declined from Sep. 2024 ($165 Mil) to Dec. 2024 ($140 Mil) and declined from Dec. 2024 ($140 Mil) to Mar. 2025 ($110 Mil).

Regeneron Pharmaceuticals's annual finished goods increased from Dec. 2022 ($99 Mil) to Dec. 2023 ($147 Mil) but then declined from Dec. 2023 ($147 Mil) to Dec. 2024 ($140 Mil).

Regeneron Pharmaceuticals Inventories, Finished Goods Historical Data

The historical data trend for Regeneron Pharmaceuticals's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Inventories, Finished Goods Chart

Regeneron Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Inventories, Finished Goods

Get a 7-Day Free Trial

121.70

73.70

98.60

147.30

139.80

Regeneron Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Inventories, Finished Goods	Get a 7-Day Free Trial															180.50	154.40	164.60	139.80	110.00

Regeneron Pharmaceuticals Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Regeneron Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (LTS:0R2M) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

REGN:USA REGN:Mexico 1REGN:Italy RGO:Germany RGO:Germany RGO:Germany REGN34:Brazil REGN:Austria

Address

777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707

Website

https://www.regeneron.com

Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals Headlines

No Headlines